The United Kingdom and the United States have concluded a key commercial pact that will guarantee no import taxes on UK pharmaceutical shipments being sold in the American market.
Key Provisions of the Pact
As part of the deal, the UK has agreed to raise spending on drugs through the public health system. This move secures that duties on these vital goods will stay at zero for a timeframe of the next three years.
This agreement comes after earlier statements to hike duties on patented pharmaceutical products, with figures discussed up to double the cost.
"This deal between the United Kingdom strengthens the global environment for cutting-edge drugs and brings long-overdue equity to transatlantic drug exports," a release declared.
Economic Importance
Drugs represent one of the UK's most significant exports to the America, which is clearly the largest market for major UK drugmakers.
Export figures reveal that in the 12 months prior to the third quarter, the UK shipped medicines totaling billions to the US. This value made up nearly one-fifth of all goods exports in that timeframe.
"This guarantee safeguards work, stimulates funding and sets the stage for the UK to establish itself as a global hub for medical research," the Business and Trade Secretary remarked.
Key UK Commitments
The deal includes several specific changes from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to increase total health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The percentage manufacturers must refund to the NHS to prevent overspending will be capped at 15%. In the past, rebates exceeded 20%.
Broader Context
The pact follows a long-running row between the drug companies and the UK government over medicine costs and approval rates.
The disagreement were intensified by claims that US customers were charged a premium for the equivalent treatments than consumers in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been delayed or scrapped, while substantial investments have been announced toward American operations.
A senior figure publicly accepted that the NHS needed to increase expenditure on medicines, noting that its spending on drugs had shrunk as a share of its overall budget over the last ten years.
